These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 29924748

  • 1. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma.
    Woodbeck R, Metelitsa AI, Naert KA.
    Am J Dermatopathol; 2018 Jul; 40(7):523-526. PubMed ID: 29924748
    [Abstract] [Full Text] [Related]

  • 2. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
    Rodriguez EF, Lipson E, Suresh K, Cappelli LC, Monaco SE, Maleki Z.
    Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
    [Abstract] [Full Text] [Related]

  • 3. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients.
    Tetzlaff MT, Nelson KC, Diab A, Staerkel GA, Nagarajan P, Torres-Cabala CA, Chasen BA, Wargo JA, Prieto VG, Amaria RN, Curry JL.
    J Immunother Cancer; 2018 Feb 12; 6(1):14. PubMed ID: 29433571
    [Abstract] [Full Text] [Related]

  • 4. Tumoral Melanosis in the Setting of Targeted Immunotherapy for Metastatic Melanoma-A Single Institutional Experience and Literature Review.
    Jurgens A, Guru S, Guo R, Brewer J, Bridges A, Jakub J, Comfere N.
    Am J Dermatopathol; 2021 Jan 01; 43(1):9-14. PubMed ID: 32149829
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Two cases of granuloma annulare under anti-PD1 therapy].
    Charollais R, Aubin F, Roche-Kubler B, Puzenat E.
    Ann Dermatol Venereol; 2018 Feb 01; 145(2):116-119. PubMed ID: 29221649
    [Abstract] [Full Text] [Related]

  • 7. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
    Yip RHL, Lee LH, Schaeffer DF, Horst BA, Yang HM.
    Melanoma Res; 2018 Dec 01; 28(6):645-647. PubMed ID: 30256271
    [Abstract] [Full Text] [Related]

  • 8. Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma.
    Danlos FX, Pagès C, Baroudjian B, Vercellino L, Battistella M, Mimoun M, Jebali M, Bagot M, Tazi A, Lebbé C.
    Chest; 2016 May 01; 149(5):e133-6. PubMed ID: 27157227
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission.
    Yatim N, Mateus C, Charles P.
    Rev Med Interne; 2018 Feb 01; 39(2):130-133. PubMed ID: 29277453
    [Abstract] [Full Text] [Related]

  • 11. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
    Earl DE, Loochtan AI, Bedlack RS.
    Muscle Nerve; 2018 Apr 01; 57(4):E120-E121. PubMed ID: 29193151
    [No Abstract] [Full Text] [Related]

  • 12. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
    Parakh S, Nguyen R, Opie JM, Andrews MC.
    Australas J Dermatol; 2017 Aug 01; 58(3):e109-e112. PubMed ID: 27170423
    [Abstract] [Full Text] [Related]

  • 13. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
    Blakeway EA, Elshimy N, Muinonen-Martin A, Marples M, Mathew B, Mitra A.
    Melanoma Res; 2019 Jun 01; 29(3):338-341. PubMed ID: 30762712
    [Abstract] [Full Text] [Related]

  • 14. Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma.
    Nardin C, Borot S, Beaudoin MA, Cattin F, Puzenat E, Gauthier AS, Schillo F, Borg C, Aubin F.
    Invest New Drugs; 2019 Apr 01; 37(2):375-377. PubMed ID: 30145624
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.
    Lomax AJ, McGuire HM, McNeil C, Choi CJ, Hersey P, Karikios D, Shannon K, van Hal S, Carr U, Crotty A, Gupta SK, Hollingsworth J, Kim H, Fazekas de St Groth B, McGill N.
    Int J Rheum Dis; 2017 Sep 01; 20(9):1277-1285. PubMed ID: 28480561
    [Abstract] [Full Text] [Related]

  • 18. Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade.
    Mauzo SH, Tetzlaff MT, Nelson K, Amaria R, Patel S, Aung PP, Nagarajan P, Torres-Cabala CA, Diab A, Prieto VG, Curry JL.
    Int J Dermatol; 2019 Sep 01; 58(9):1045-1052. PubMed ID: 29152725
    [Abstract] [Full Text] [Related]

  • 19. Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases.
    Jespersen H, Bjursten S, Ny L, Levin M.
    Lancet Oncol; 2018 Jun 01; 19(6):e327. PubMed ID: 29893264
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.